PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 24291173-10 2014 Furthermore, olmesartan down-regulated matrix metalloproteinase-2 and angiotensin II type I receptor expression in the kidney. olmesartan 13-23 angiotensinogen Rattus norvegicus 70-84 32106816-7 2020 High-dose nitrate or olmesartan alone, and especially in combination, decreased the levels of PRA and angiotensin II and downregulated the CHF-induced expression of AT1R, alpha1A-, beta1-, and beta2-AR, and AT2R. olmesartan 21-31 angiotensinogen Rattus norvegicus 102-116 32585603-12 2020 Olmesartan decreased the expression of Ang II and AT1, but further increased the expression of Apelin and APJ. olmesartan 0-10 angiotensinogen Rattus norvegicus 39-45 32585603-14 2020 CONCLUSION: Olmesartan inhibits the intimal thickening through activating Apelin/APJ and inhibiting AngII-AT1 and ERK pathway. olmesartan 12-22 angiotensinogen Rattus norvegicus 100-105 28656296-6 2017 In addition, telmisartan and olmesartan was indicated to antagonize angiotensin II (Ang II) and upregulate ACE2, MasR, Ang (1-7) expression in myocardial tissue using immunoassay and ELISA test, and the effect of Olm was more marked than that of Tel at the same dosage. olmesartan 29-39 angiotensinogen Rattus norvegicus 68-82 28656296-6 2017 In addition, telmisartan and olmesartan was indicated to antagonize angiotensin II (Ang II) and upregulate ACE2, MasR, Ang (1-7) expression in myocardial tissue using immunoassay and ELISA test, and the effect of Olm was more marked than that of Tel at the same dosage. olmesartan 29-39 angiotensinogen Rattus norvegicus 84-90 26763849-4 2016 RGS2 mRNA expression significantly increased with Ang II stimulation, and this increase was almost completely abolished by olmesartan, a potent AT1R-specific blocker. olmesartan 123-133 angiotensinogen Rattus norvegicus 50-56 26763849-8 2016 Moreover, pretreatment with olmesartan abolished Ang II-mediated RGS2 mRNA expression. olmesartan 28-38 angiotensinogen Rattus norvegicus 49-55 25487981-6 2015 RESULTS: Compared with the CHF group, PRA and Ang II levels were decreased while heart function and mRNA and protein expression of alpha1A-AR, beta1-AR and beta2-AR were up-regulated in the olmesartan group (p<0.05 or p<0.01). olmesartan 190-200 angiotensinogen Rattus norvegicus 46-52 25487981-8 2015 CONCLUSION: Olmesartan may play a beneficial role in protecting lung in CHF by up-regulating AR and decreasing levels of PRA and Ang II. olmesartan 12-22 angiotensinogen Rattus norvegicus 129-135 24847907-7 2014 Ang II (10(-7) mol/L, 48 h)-induced increase in the LC3-II to LC3-I ratio, the formation of autophagosomes, expression of beclin-1 and decrease in the expression of SQSTM1/p62 were also inhibited by pretreatment with 3-methyladenine or bafilomycin A1 (inhibitors of autophagy), olmesartan and candesartan (in dose-dependent manners), apocynin, 5HD, and siRNA Atg5. olmesartan 278-288 angiotensinogen Rattus norvegicus 0-6 25089522-8 2014 Olmesartan (an Ang II receptor antagonist) prevented the upregulation of CARP in both Ang II-stimulated NRVCs and hearts with pressure overload. olmesartan 0-10 angiotensinogen Rattus norvegicus 15-21 25089522-8 2014 Olmesartan (an Ang II receptor antagonist) prevented the upregulation of CARP in both Ang II-stimulated NRVCs and hearts with pressure overload. olmesartan 0-10 angiotensinogen Rattus norvegicus 86-92 24847907-6 2014 Increased ROS production induced by Ang II was inhibited by Ang II type 1 receptor (AT1) blockers (Olmesartan and Candesartan, ARB), a NADPH Oxidase inhibitor (apocynin), and mitochondrial KATP channels inhibitor (5-hydroxydecanoate, 5HD). olmesartan 99-109 angiotensinogen Rattus norvegicus 36-42 24910532-10 2014 Chronic treatment with olmesartan ameliorated these areas of augmented angiotensinogen expression. olmesartan 23-33 angiotensinogen Rattus norvegicus 71-86 24770651-5 2014 Administration of the AT1R antagonist olmesartan resulted in the restoration of the reduction of apelin and APJ expressions induced by AngII for 48 h in 3T3-L1 adipocytes. olmesartan 38-48 angiotensinogen Rattus norvegicus 135-140 24770651-7 2014 In addition, the levels of p-Akt, p-ERK and p38MAPK proteins were decreased by long-term treatment with AngII (120 min), and these changes were restored by Olmesartan. olmesartan 156-166 angiotensinogen Rattus norvegicus 104-109 24342995-9 2013 Olmesartan and mitogen-activated protein kinase inhibitor decreased the CatK expression induced by angiotensin II in rat neonatal myocytes. olmesartan 0-10 angiotensinogen Rattus norvegicus 99-113 19662023-6 2009 In immunohistological analysis, all areas positive for angiotensin II, p22(phox) and 4-hydroxy-2-nonenal were significantly reduced by olmesartan and valsartan, but again this reduction was significantly greater for olmesartan. olmesartan 135-145 angiotensinogen Rattus norvegicus 55-69 22318512-1 2012 BACKGROUND: Studies were performed to determine if early treatment with an angiotensin II (Ang II) receptor blocker (ARB), olmesartan, prevents the onset of microalbuminuria by attenuating glomerular podocyte injury in Otsuka Long-Evans Tokushima Fatty (OLETF) rats with type 2 diabetes mellitus. olmesartan 123-133 angiotensinogen Rattus norvegicus 91-97 21716329-8 2011 Both the Ang II receptor blocker, RNH-6270 (100 nmol/l), and an antioxidant, ebselen (40 micromol/l), inhibited vascular cell hypertrophy. olmesartan 34-42 angiotensinogen Rattus norvegicus 9-15 20965209-6 2010 Treatment with an angiotensin II receptor antagonist, olmesartan, in a vessel bath augmented vasodilation in old-M+young-A (34.9+-4.0%, P<0.01) and old-M+old-A (27.2+-2.8%, P<0.01). olmesartan 54-64 angiotensinogen Rattus norvegicus 18-32 20601457-7 2010 The inhibitory action of ANG II was antagonized by RNH-6270 (an angiotensin type 1 receptor antagonist) but not by PD-122370 (an angiotensin type 2 receptor antagonist). olmesartan 51-59 angiotensinogen Rattus norvegicus 25-31 20827339-1 2010 The present sutdy aimed to determine whether olmesartan, an angiotensin II (Ang II) type 1 (AT(1)) receptor blocker, can influence the CA release from the isolated perfused model of the rat adrenal medulla. olmesartan 45-55 angiotensinogen Rattus norvegicus 76-82 20827339-4 2010 Also, in adrenal glands loaded with olmesartan (15 microM), the CA secretory responses evoked by Bay-K-8644 (10 microM, an activator of voltage-dependent L-type Ca(2+) channels), cyclopiazonic acid (10 microM, an inhibitor of cytoplasmic Ca(2+) -ATPase), veratridine (100 microM, an activator of voltage-dependent Na(+) channels), and Ang II (100 nM) were markedly inhibited. olmesartan 36-46 angiotensinogen Rattus norvegicus 335-341 23459599-1 2013 BACKGROUND: We investigated whether the antihypertensive actions of the angiotensin II (Ang II) receptor (AT(1)-R) blocker, olmesartan medoxomil, may in part be mediated by increased Ang-(1-7) in the absence of significant changes in plasma Ang II. olmesartan 124-134 angiotensinogen Rattus norvegicus 88-94 23459599-5 2013 RESULTS: Antihypertensive effects of olmesartan were associated with an increase in plasma renin concentration, plasma Ang I, Ang II, and Ang-(1-7), whereas serum aldosterone levels and kidney Ang II content were reduced. olmesartan 37-47 angiotensinogen Rattus norvegicus 126-132 23698111-2 2013 We examined whether treatment with an angiotensin-converting enzyme (ACE) inhibitor, temocapril, or an AT1-receptor blocker, olmesartan, prevented elevation of Ang II levels in the kidney of angiotensin I (Ang I)-infused rats. olmesartan 125-135 angiotensinogen Rattus norvegicus 160-166 23698111-8 2013 Interestingly, temocapril failed to reduce the level of Ang II in the kidney, while olmesartan markedly suppressed an increase in renal Ang II levels. olmesartan 84-94 angiotensinogen Rattus norvegicus 136-142 22496409-6 2012 Olmesartan decreased cortical prorenin, non-proteolytically activated prorenin and ANG II, and apical membranous PRR in the collecting ducts and connecting tubules, and attenuated the renal lesions. olmesartan 0-10 angiotensinogen Rattus norvegicus 83-89 21602711-9 2011 These beneficial effects of olmesartan were associated with ANG II and insulin receptor upregulation in sensory neurons as well as deactivation of Erk1/2 in sciatic nerves. olmesartan 28-38 angiotensinogen Rattus norvegicus 60-66 21602711-10 2011 CONCLUSION: Olmesartan appears to improve the structure and function of small and large nerves and upregulate ANG II and insulin receptors in sensory neurons of rats with type 2 diabetes. olmesartan 12-22 angiotensinogen Rattus norvegicus 110-116 21536991-7 2011 Olmesartan also increased mRNA expression of angiotensin-converting enzyme 2, Bcl-2, and Bcl-xL and reduced angiotensin II and cleaved caspase 3. olmesartan 0-10 angiotensinogen Rattus norvegicus 108-122 21536991-10 2011 These findings suggest that the transactivation of neuroprotective genes and the reduction in brain angiotensin II are ERalpha dependent and that this may augment neuroprotection together with an angiotensin II type 1 receptor blockade by olmesartan. olmesartan 239-249 angiotensinogen Rattus norvegicus 100-114 20876084-9 2010 Further, the plasma level of angiotensin II was significantly increased in olmesartan-treated rats. olmesartan 75-85 angiotensinogen Rattus norvegicus 29-43 18256306-4 2008 Of importance, Ang II significantly induced the expression of receptor activator of NF-kappaB ligand (RANKL) in osteoblasts, leading to the activation of osteoclasts, whereas these effects were completely blocked by an Ang II type 1 receptor blockade (olmesartan) and mitogen-activated protein kinase kinase inhibitors. olmesartan 252-262 angiotensinogen Rattus norvegicus 15-21 19261744-4 2009 With olmesartan [Ang II type 1 receptor (AT1R) antagonist] pretreatment, p-ERK plateau levels decreased in a dose-dependent manner (EC(50) = 1.3 x 10(-8) M, maximal inhibition 50.6 +/- 11.0% at 10(-5) M); a similar effect was observed with RNA interference against Ang II type 1A receptor (AT(1A)R) and Tempol, a superoxide dismutase mimetic. olmesartan 5-15 angiotensinogen Rattus norvegicus 17-23 19466524-12 2009 The differential action of olmesartan suggests that it is essential to block growth stimulation by angiotensin II in cardiomyocytes and vascular smooth muscle cells in order to better prevent cardiovascular adverse remodeling due to arterial hypertension. olmesartan 27-37 angiotensinogen Rattus norvegicus 99-113 19171689-11 2009 Olmesartan improved left ventricular function and hypertrophy through the increase of the ACE2 mRNA and decrease of both angiotensin II and ERK mRNA in pressure-overload rat heart. olmesartan 0-10 angiotensinogen Rattus norvegicus 121-135 18725581-4 2008 However, treatment with olmesartan, an Ang II type 1 receptor-specific antagonist, either at a depressor or subdepressor dose, recovered the suppressed cardiac ATRAP to Ang II type 1 receptor ratio, which was accompanied by a decrease in Ang II type 1 receptor density, an inhibition of p38 mitogen-activated protein kinase activity, and a regression of cardiac hypertrophy. olmesartan 24-34 angiotensinogen Rattus norvegicus 39-45 18725581-4 2008 However, treatment with olmesartan, an Ang II type 1 receptor-specific antagonist, either at a depressor or subdepressor dose, recovered the suppressed cardiac ATRAP to Ang II type 1 receptor ratio, which was accompanied by a decrease in Ang II type 1 receptor density, an inhibition of p38 mitogen-activated protein kinase activity, and a regression of cardiac hypertrophy. olmesartan 24-34 angiotensinogen Rattus norvegicus 169-175 18725581-4 2008 However, treatment with olmesartan, an Ang II type 1 receptor-specific antagonist, either at a depressor or subdepressor dose, recovered the suppressed cardiac ATRAP to Ang II type 1 receptor ratio, which was accompanied by a decrease in Ang II type 1 receptor density, an inhibition of p38 mitogen-activated protein kinase activity, and a regression of cardiac hypertrophy. olmesartan 24-34 angiotensinogen Rattus norvegicus 169-175 18725581-6 2008 These findings show a tissue-specific regulatory balancing of the expression of ATRAP and Ang II type 1 receptor during the development of hypertension and cardiac remodeling and further suggest that the upregulation of the tissue ATRAP to Ang II type 1 receptor ratio may be one of the therapeutic benefits of olmesartan beyond its blood pressure-lowering effect. olmesartan 311-321 angiotensinogen Rattus norvegicus 90-96 18725581-6 2008 These findings show a tissue-specific regulatory balancing of the expression of ATRAP and Ang II type 1 receptor during the development of hypertension and cardiac remodeling and further suggest that the upregulation of the tissue ATRAP to Ang II type 1 receptor ratio may be one of the therapeutic benefits of olmesartan beyond its blood pressure-lowering effect. olmesartan 311-321 angiotensinogen Rattus norvegicus 240-246 18583318-7 2008 Finally, olmesartan and apocynin reduced angiotensin II-induced increases in cathepsin mRNA and protein levels in cultured rat neonatal cardiac myocytes. olmesartan 9-19 angiotensinogen Rattus norvegicus 41-55 18256306-4 2008 Of importance, Ang II significantly induced the expression of receptor activator of NF-kappaB ligand (RANKL) in osteoblasts, leading to the activation of osteoclasts, whereas these effects were completely blocked by an Ang II type 1 receptor blockade (olmesartan) and mitogen-activated protein kinase kinase inhibitors. olmesartan 252-262 angiotensinogen Rattus norvegicus 219-225 18633182-7 2008 This finding was supported by the anti-hypertrophic and anti-fibrotic actions of RNH6270, an active form of olmesartan, on MCs in the MC/NMC co-culture system and on NMCs that may synthesize Ang II in the heart. olmesartan 81-88 angiotensinogen Rattus norvegicus 191-197 18633182-7 2008 This finding was supported by the anti-hypertrophic and anti-fibrotic actions of RNH6270, an active form of olmesartan, on MCs in the MC/NMC co-culture system and on NMCs that may synthesize Ang II in the heart. olmesartan 108-118 angiotensinogen Rattus norvegicus 191-197 17345786-10 2006 Interestingly, co-administration of (D-Ala7)-Ang-(1-7) with olmesartan significantly increased the plasma Ang II level (453.2+/-113.8 pg/ml) compared to olmesartan alone (144.9+/-27.0 pg/ml, p<0.05). olmesartan 60-70 angiotensinogen Rattus norvegicus 106-112 18360051-4 2008 Ang II increased superoxide generation in isolated normal glomeruli in a dose-dependent manner, and co-incubation with olmesartan, an angiotensin type 1 receptor blocker, suppressed such increase. olmesartan 119-129 angiotensinogen Rattus norvegicus 0-6 17345786-3 2006 However, Ichikawa (Hypertens Res 2001; 24: 641-646) reported that long-term treatment of hypertensive patients with olmesartan resulted in a reduction in plasma Ang II level, though the mechanism was not determined. olmesartan 116-126 angiotensinogen Rattus norvegicus 161-167 16934905-3 2007 A mixture of insulin and Ang II additively increased the values of [(3)H]-thymidine incorporation in WF and WL, which was inhibited by olmesartan, an AT1 receptor blockade (ARB), but not by PD123,319, an AT2 receptor blockade. olmesartan 135-145 angiotensinogen Rattus norvegicus 25-31 17345786-13 2006 These findings suggest that olmesartan may exhibit an ACE inhibitory action in addition to an Ang II receptor blocking action, prevent an increase in Ang II level, and protect cardiovascular remodeling through an increase in cardiac nitric oxide production and endogenous Ang-(1-7) via over-expression of ACE2. olmesartan 28-38 angiotensinogen Rattus norvegicus 94-100 17345786-13 2006 These findings suggest that olmesartan may exhibit an ACE inhibitory action in addition to an Ang II receptor blocking action, prevent an increase in Ang II level, and protect cardiovascular remodeling through an increase in cardiac nitric oxide production and endogenous Ang-(1-7) via over-expression of ACE2. olmesartan 28-38 angiotensinogen Rattus norvegicus 150-156 16767106-8 2006 Ang II induced Col4 synthesis and increased expression of phospho-Src and phospho-Smad1 in cultured mesangial cells, which was blocked by olmesartan. olmesartan 138-148 angiotensinogen Rattus norvegicus 0-6 16685209-5 2006 The increases in p22-phox mRNA levels induced by a stretch force in combination with angiotensin II were prevented by treatment with an angiotensin type I (AT1) receptor antagonist, RNH-6270 (100 nmol/l). olmesartan 182-190 angiotensinogen Rattus norvegicus 85-99 16331107-6 2006 In the AII-infused rats treated with olmesartan medoxomil, an AT1R blocker, we were interested to observe significant decreases in plasma TC and non-high-density lipoprotein (HDL)-cholesterol (C) (TC minus HDL-C), and liver cholesterol content were also decreased. olmesartan 37-47 angiotensinogen Rattus norvegicus 7-10 16546478-7 2006 An AII type 1 receptor blocker, olmesartan, restored the low adiponectinemia induced by the AII infusion (50 ng/kg per minute). olmesartan 32-42 angiotensinogen Rattus norvegicus 3-6 16546478-7 2006 An AII type 1 receptor blocker, olmesartan, restored the low adiponectinemia induced by the AII infusion (50 ng/kg per minute). olmesartan 32-42 angiotensinogen Rattus norvegicus 92-95 16755152-10 2006 Olmesartan at 10 mg/kg/day tended to decrease renal cortical and medullary Ang II levels, TGF-beta and CTGF expression, and collagen contents; however, these changes were not significant. olmesartan 0-10 angiotensinogen Rattus norvegicus 75-81 16331107-9 2006 The AII infusion led to significant elevations in TC and non-HDL-C in the fructose-fed rats, and olmesartan treatment completely rectified this AII-induced hypercholesterolemia. olmesartan 97-107 angiotensinogen Rattus norvegicus 144-147 16053988-6 2005 Olmesartan or atenolol reduced arteriolar wall-to-lumen ratio (olmesartan: 11.5+/-0.4%; atenolol: 13.3+/-0.6%; vehicle: 18.4%+/-1.1); however, this effect was greatest in rats medicated with the angiotensin II type 1 antagonist. olmesartan 0-10 angiotensinogen Rattus norvegicus 195-209 16143317-2 2005 The aim of the present study was to determine the effect of chronic oral treatment with a new angiotensin II type 1 (AT(1)) receptor antagonist, RNH-6270 (the active form of olmesartan medoxomil), on cardiovascular responses to excitatory amino acids in the RVLM of SHR. olmesartan 145-153 angiotensinogen Rattus norvegicus 94-108 16419651-11 2005 In addition, the facts that olmesartan increased cAMP and decreased TNF-alpha suggest that a part of the TNF-alpha regulation by angiotensin II might consist of modulation of cAMP through Gi protein activation in skeletal muscle. olmesartan 28-38 angiotensinogen Rattus norvegicus 129-143 16143317-7 2005 These results demonstrated that chronic oral treatment with RNH-6270, an AT(1) receptor antagonist, partly normalizes the pressor responses to L-glutamate or NMDA, but not (1S,3R)-ACPD, in the RVLM of SHR, suggesting that endogenous angiotensin II may be involved in the exaggerated pressor response to l-glutamate, probably through its ionotropic glutamate receptors. olmesartan 60-68 angiotensinogen Rattus norvegicus 233-247 15963646-10 2005 Paralleling these effects on cerebral ischemia, olmesartan treatment also reduced the reactive upregulation in brain angiotensin II, matrix metalloproteinase-2, matrix metalloproteinase-9, and membrane type 1-matrix metalloproteinase in the ischemic area. olmesartan 48-58 angiotensinogen Rattus norvegicus 117-131 15867141-4 2005 Also, an angiotensin II type 1 (AT1) receptor blocker (olmesartan) inhibited EC apoptosis, whereas angiotensin II administration accelerated apoptosis independently of blood pressure. olmesartan 55-65 angiotensinogen Rattus norvegicus 9-23 15867141-7 2005 Conversely, temocapril and olmesartan reduced apoptosis and 8-isoprostane formation induced by H2O2, suggesting that endogenous angiotensin II interacts with H2O2 to elevate oxidative stress levels and EC apoptosis. olmesartan 27-37 angiotensinogen Rattus norvegicus 128-142 16416656-0 2005 The angiotensin-II (AT-II) receptor blocker olmesartan reduces renal damage in animal models of hypertension and diabetes. olmesartan 44-54 angiotensinogen Rattus norvegicus 4-18 14732213-6 2004 RESULTS: Ang II-increased DNA synthesis was inhibited by AT(1) receptor antagonist (olmesartan) and ET(A) receptor antagonist (BQ485). olmesartan 84-94 angiotensinogen Rattus norvegicus 9-15 14732213-8 2004 Ang II-increased intracellular ROS levels were inhibited by olmesartan and antioxidants. olmesartan 60-70 angiotensinogen Rattus norvegicus 0-6 12871826-2 2003 We studied the effect of a new angiotensin II type 1 (AT(1)) receptor antagonist, olmesartan medoxomil (olmesartan), on the fibrogenic responses in rat hepatic stellate cells (HSCs) and liver fibrogenesis. olmesartan 82-92 angiotensinogen Rattus norvegicus 31-45 12871826-0 2003 An angiotensin II type 1 receptor antagonist, olmesartan medoxomil, improves experimental liver fibrosis by suppression of proliferation and collagen synthesis in activated hepatic stellate cells. olmesartan 46-56 angiotensinogen Rattus norvegicus 3-17 12871826-10 2003 Olmesartan blocked all these effects of Ang II. olmesartan 0-10 angiotensinogen Rattus norvegicus 40-46 8566137-4 1995 In conscious rats, intravenously injected RNH-6270 inhibited angiotensin II-induced pressor responses in a dose-dependent manner, and orally administered CS-866 produced a long-lasting inhibition of angiotensin II pressor responses. olmesartan 42-50 angiotensinogen Rattus norvegicus 61-75 14574081-0 2003 Effects of olmesartan, an angiotensin II receptor blocker, on mechanically-modulated genes in cardiac myocytes. olmesartan 11-21 angiotensinogen Rattus norvegicus 26-40 24817138-10 2015 In contrast, although treatment with olmesartan (10 mg/kg/day) for 14 days suppressed an increase of intrarenal AGT, olmesartan did not alleviate ischemic AKI, along with no change of (P)RR and phosphorylated ERK 1/2. olmesartan 37-47 angiotensinogen Rattus norvegicus 112-115